Neogenomics (NEO) Liabilities and Shareholders Equity (2010 - 2026)

Neogenomics (NEO) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 billion in Q2 2026.

• Quarterly Liabilities and Shareholders Equity fell 2.99% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.4 billion (down 13.41% YoY) and the FY2025 annual result came in at $1.4 billion, down 16.98% from the prior year.
• Liabilities and Shareholders Equity steadied at $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.8 billion in Q1 2022 to a low of $1.3 billion in Q1 2026.
• A 5-year average of $1.6 billion and a median of $1.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity climbed 22.43% — and 2025, when it dropped 16.98%.
• Tracing NEO's Liabilities and Shareholders Equity over 5 years: stood at $1.7 billion in 2022, then slipped by 3.38% to $1.7 billion in 2023, then declined by 2.57% to $1.6 billion in 2024, then retreated by 16.98% to $1.4 billion in 2025, then fell by 0.56% to $1.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.4 billion (Q4 2025), per Business Quant data.